In contrast, SC-236, a structural analog of the clinically useful COX-2 inhibitor celecoxib, reduced the expression of Nr4a factors as well as Foxp3 and Ikzf4 in tumor Treg cells. This evidence concerns the gene FOXP3 and neoplasm.